Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

9.78
+0.57006.19%
Post-market: 9.780.00000.00%19:30 EDT
Volume:1.76M
Turnover:17.03M
Market Cap:1.65B
PE:-5.76
High:9.86
Open:9.31
Low:9.31
Close:9.21
52wk High:11.66
52wk Low:4.35
Shares:168.65M
Float Shares:130.00M
Volume Ratio:1.24
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6972
EPS(LYR):-3.1619
ROE:-26.08%
ROA:-14.51%
PB:1.68
PE(LYR):-3.09

Loading ...

Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.

Benzinga Earnings
·
May 07

Vir Biotechnology Inc - Topline Data From Phase 3 Eclipse 1 Trial Expected in Q4 2026

THOMSON REUTERS
·
May 07

Vir Biotechnology CEO joins Bank of America Securities Healthcare Conference fireside chat

Reuters
·
May 06

How Insider Sale and VIR-5500 Milestone at Vir Biotechnology (VIR) Have Changed Its Investment Story

Simply Wall St.
·
May 05

Vir director Vicki L. Sato disposes of 22,000 shares worth $221,025.20

Reuters
·
May 05

Earning Preview: Vir Biotechnology, Inc. Q1 revenue is expected to increase by 1,171.96%, and institutional views are bullish

Earnings Agent
·
Apr 30

Barclays Remains a Buy on Vir Biotechnology (VIR)

TIPRANKS
·
Apr 28

Vir Biotechnology to host conference call on first-quarter results and corporate update

Reuters
·
Apr 24

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows

Simply Wall St.
·
Apr 21

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

TIPRANKS
·
Apr 16

Vir Biotechnology announces annual shareholder meeting

Reuters
·
Apr 16

Vir Biotechnology, Astellas form global collaboration on prostate cancer drug VIR-5500

Reuters
·
Apr 16

Vir Biotechnology Announces Closing of Global Strategic Collaboration With Astellas for the Treatment of Prostate Cancer

THOMSON REUTERS
·
Apr 16

Vir Biotechnology Inc - Eligible for $20 Mln Near-Term and up to $1.37 Bln in Additional Milestones

THOMSON REUTERS
·
Apr 16

Vir Biotechnology Inc - Receives $240 Mln Upfront and $75 Mln Equity Investment at $10.36 per Share

THOMSON REUTERS
·
Apr 16

Brii Biosciences files arbitration demand against Vir over elebsiran manufacturing transfer

Reuters
·
Apr 16

Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer

Reuters
·
Apr 13

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-Expansion Cohorts Evaluating Psma-Targeted, Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Patients With Metastatic Prostate Cancer

THOMSON REUTERS
·
Apr 13

Vir Biotechnology Inc - Vir-5500 Combination Cohorts to Begin Soon; Phase 3 Trials Planned for 2027

THOMSON REUTERS
·
Apr 13

Vir Biotechnology CMO Mark Eisner to step down April 24

Reuters
·
Apr 11